Mohamad Khawandanah

Clinical trials

• Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2024–2029
• A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  Site PI · Recruiting · Phase 1

  National Cancer Institute (NCI)

  2024–2027
• Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  Site PI · Recruiting · Phase 3

  National Cancer Institute (NCI)

  2021–2028
• Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2017–2027